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Background
The World Health Organization defines frailty as “a 
clinically recognizable state in which the ability of older people 
to cope with everyday or acute stressors is compromised by 
an increased vulnerability brought by age-associated declines 
in physiological reserve and function across multiple organ 
systems.”(1) Improving outcomes, meeting the needs of 
those living with frailty, and ensuring the best use of limited 
resources pose challenges for healthcare systems (2). In spite 
of the increasing number of frailty publications, high-quality 
evidence for decision making is often lacking because a) 
participants living with frailty are often excluded from clinical 
trials; b) studies enrolling older adults rarely consider the 
differential impact of frailty and c) frailty is often poorly 
measured or characterized (3-5).
To better understand the state of frailty research, it is 
informative to examine frailty randomized controlled trials 
(RCTs). Although RCTs are regarded as providing the highest 
quality of evidence, the number of trials primarily enrolling 
individuals with well-characterised frailty using validated 
measures is relatively low (6, 7).  A recent systematic review of 
209 trials conducted to date found that the majority did not use 
validated frailty criteria and were inconsistent in characterizing 
frailty, including variable description of function, medication 
utilization, quality of life, and cognitive status (8). Poor 
definition of participant populations lowers the quality of an 
RCT (9).  In addition, outcomes reported in RCTs varied, with 
function-based outcomes measured by a variety of methods 
being the most common (10). Other outcomes included changes 
in severity of frailty as assessed by a variety of criteria and 
laboratory-based outcomes. Further, the importance of many of 
these outcomes to persons living with frailty is unknown.  
Inadequate descriptions of the populations enrolled including 
frailty severity and frailty conceptualization, lack of use of 
validated frailty assessment tools, utilization of different frailty 
instruments between studies, and variation in the outcomes 
measured impairs the ability to interpret, generalize and 
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implement the research findings. In addition, the lack of study 
standardization limits the ability to aggregate evidence through 
data syntheses and meta-analyses. As a result, when deciding on 
an intervention/treatment or system change, care providers and 
decision makers are often left with unanswered questions: does 
evidence generated in non-frail patients have similar risks and 
benefits in a person with frailty and to what degree of frailty? 
Were the patients studied similar to ones in my care? As a 
consequence, treatments are often applied to those with frailty 
where evidence for effectiveness or harm is lacking, risking 
inappropriate resource utilization. Conversely, interventions 
not effective in non-frail patients may actually be effective in 
those who are frail but may never be utilized due to a lack of 
evidence.    
The lack of standardization in clinical trials is not unique to 
frailty studies and has been described for other disciplines and 
diseases (11). In addition, there have been increasing calls on 
the part of regulatory agencies and funders to standardize the 
conduct and reporting of clinical trials (12). The utilization of 
common data elements (CDEs) and core outcome measures 
(COMs) in clinical trials is increasingly being adopted (e.g., 
stroke, rheumatoid arthritis, traumatic brain injury) (13-16). 
To catalyze the development and use of CDEs and COMs for 
future frailty studies, the Canadian Frailty Network (www.cfn-
nce.ca; CFN), a not-for-profit pan-Canadian nationally-funded 
research network, convened an international group of experts to 
examine the issue and plan the path forward on March 4, 2018. 
For this meeting, we defined CDEs and COMs as follows. 
CDEs are a minimum standardised set of data elements that 
would be collected in all frailty studies including population 
descriptor elements and standardized frailty assessments. COMs 
are a minimum standardized list of outcomes to be reported in 
all relevant clinical frailty studies. In addition to the CDEs and 
COMs, investigators would be expected to collect any other 
study specific data/information.  The objectives of meeting 
were to: 
1. Enable collaborative learning from the expertise of the 
attendees 
2. Learn from existing data and outcome standardization 
initiatives
3. Identify opportunities and challenges for the development of 
frailty CDEs and COMs
4. Develop a path forward for the development of frailty CDEs 
and COMs
Purposeful sampling for meeting invitees was conducted 
with the criteria that they had published in the field of frailty, 
were representative of organizations representing or working 
with ageing populations/older people, or were representatives of 
organizations that were active in developing CDEs and COMs. 
It was agreed at the onset of the meeting that a consensus 
statement based on the meeting would be published and herein 
we report the statement. 
Learning from other CDEs and COMs initiatives
Three organizations were invited to present at the meeting. 
One of the oldest initiatives aimed at standardizing outcomes in 
interventional trials is the Outcome Measures in Rheumatology 
Trials (OMERACT) (www.omeract.org) (13, 17). Since its 
inception in 1992, the OMERACT core outcome set has been 
used in over 1,000 peer-reviewed articles, is currently being 
utilized in 70% of rheumatoid pharmaceutical studies, and 
is recognized by the European Medicines Agency (EMA), 
Food and Drug Administration (FDA) and the World Health 
Organization (WHO) (18). The Core Outcome Measures 
in Effectiveness Trials (COMET) initiative brings together 
stakeholders to develop and apply agreed upon standardized 
sets of outcomes (www.comet-initiative.org) (19). The COMET 
initiative lists over 300 core outcome measure sets with work 
being done on a further 188 (20). The International Consortium 
for Health Outcomes Measurement (ICHOM) is a non-profit 
organization founded in 2012 whose mission is to unlock the 
potential of value-based health care by defining global standard 
sets of outcome measures that matter to patients (www.ichom.
org) (21). Key concepts that emerged from these organizations 
which should be implemented in the development of frailty 
CDEs and COMs are:
1. The conceptual framework and necessary domains both 
by quantitative and qualitative means through a systematic 
review of the literature and by surveying the views of 
patients, caregivers and stakeholders must be defined first.
2. Prior to the adoption of any CDEs and COMs, it is necessary 
to evaluate their measurement properties and feasibility 
(22). Each instrument/measure should be evaluated through 
robust processes on the basis of their diagnostic accuracy, 
discriminative ability, reliability, validity, feasibility and 
sensitivity to change. Sensitivity to change for outcomes in 
the frailty literature has been poorly studied and this should 
be a key area of future investigation. The preference is for 
previously developed high-quality instruments that have 
undergone quality assessment; new instruments should not 
need to be developed. It is important to evaluate if a measure 
is difficult or resource intensive to use since it may pose a 
barrier to its widespread adoption.
3. The conceptualization of hierarchies of data to be collected is 
necessary. This has been referred to as a data onion with the 
elements necessary in all studies at the center, upon which 
are layered additional data elements arising from study type 
and investigator requirement (23, 24). 
4. The process of developing CDEs and COMs needs to 
include stakeholder input including clinicians, patients/
caregivers, patient representatives and decision makers (25). 
It should include the consideration of two components; 
what should be measured and how should it be measured? 
Defining appropriate language and outcome measures 
that are meaningful to patients and their caregivers orients 
discussions and their contributions should be highly visible 
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and recognized.
5. A transparent process is necessary to choose CDEs and 
COMs; the scoring process, definition for consensus and 
selection process need to be set a priori. International 
consensus is desirable and Delphi surveys are useful to arrive 
at consensus in a large number of participants (26).
6. For relevance, outcomes should be tailored to the research 
question (27). This may extend to the instruments chosen. 
However, the CDEs should remain the same.
CDEs and COMs considerations specific to frailty
Defining frailty and frail populations
The frailty research community has made progress 
in harmonizing schools of thought as to the underlying 
conceptualisation of frailty (28). The two main conceptual 
models characterize frailty as a phenotype (29) or as an 
accumulation of deficits (30) although other models have 
also been developed, emphasizing function, bio-psycho-
social aspects, and dynamic interaction with environment. 
The definition of frailty as a state of heightened vulnerability 
is shared among these models. Frailty measurement tools 
capture these concepts of frailty, from physical phenotype 
and performance-based measures, through to judgment and 
questionnaire-based measures that emphasize the stochastic 
and multidimensional constructs. In addition, the concept of 
intrinsic capacity, defined as the composite of physical and 
mental capacities that underlie an individual, has recently 
emerged (31). Intrinsic capacity is complementary to the 
construct of frailty, is inherently multidimensional, and is 
based on the evaluation of assets (residual reserves/capacities) 
rather than deficits. The development of measurement tools 
for intrinsic capacity is proceeding (1). Although the evolving 
conceptualization of frailty has enriched our knowledge of 
the complexity of aging, the variety of different measurement 
tools being used have limited the generalizability of the 
knowledge generated. Going forward, it will be important for 
the development of frailty CDEs and COMs that these different 
concepts are captured to the greatest extent possible.
Current common practices for the identification of frailty 
in studies include subjective assessment based on care setting 
such as residence in an assisted-living facility or admission to 
a geriatric inpatient unit. Although setting-based definitions 
of frailty may appear to be more objective and settings maybe 
useful for screening or study population enrichment, they 
should be avoided as descriptors for assessments of frailty 
since there often exists heterogeneity between settings, regions, 
or nations and it has been shown that there is a large degree 
of variability in the severity of frailty in long-term care home 
residents (32). In addition, frailty is at times equated with 
advanced age or the presence of comorbidities; these have all 
been shown to have poor discriminative ability (33, 34). These 
characterizations have been used to define frailty in studies and 
these differences impair the generalizability and evaluation 
of these studies, particularly for international comparative 
analyses.
Challenges in engaging older persons living with frailty 
and their caregivers
The involvement of older persons living with frailty in the 
development of CDEs and COMs is challenging due to the 
high prevalence of cognitive impairment, physical disability 
and declining health over the long period of time that the 
development of these initiatives requires (35). While the 
involvement of caregivers may be more feasible, it is important 
that older people living with frailty be included as much as 
possible. An additional challenge is the selection bias inherent 
in convenience/volunteer samples such that highly engaged 
older people may be more robust (i.e. less frail)  or be of a 
higher socioeconomic status and have a very different outlook 
on priorities for their care than those who live with severe 
frailty and thus not representative of the overall frail population. 
When recruiting older people for development of CDEs and 
COMs, self-reported poor health could be used as a surrogate 
for frailty to avoid the lack of participants who may not have 
already been identified as frail in their clinical environments 
(36).
Path Forward
Scope of the Initiative
Although it would be desirable to have harmonised CDEs 
and COMs for both frailty research and administrative data 
collection, to increase the feasibility and likelihood of success, 
initial efforts should focus on frailty research of any study 
design including trials of frailty interventions and purely 
observational studies, with the aim of harmonizing with 
administrative data sets in the future. Given the heterogeneity 
of possible interventions from patient level to system-wide 
interventions, overarching COMs will likely not be feasible. 
COMs will need to be tailored to the type of frailty study, 
interventions or care settings. As an example, in early phase 
clinical trials, non-patient centered outcomes such as a change 
in a biomarker may be important, but not as important for later 
phase trials. In contrast, there was agreement that it will be 
possible to develop overarching CDEs for frailty studies. 
Feasibility
Overall, there was agreement that this initiative was feasible 
going forward both in the ability to arrive at CDEs, tailored 
COMs and the ability to implement them in future research. 
Implementation will depend on data collection burden and the 
tools or instruments adopted.  Funders of research (e.g. CFN) 
and health systems funders could also move the process forward 
by mandating the collection of minimum data sets in funded 
studies. Although this initiative originated from Canada, it 
should have worldwide representation since the international 
community would benefit from improving frailty research and 
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international input would increase its adoption worldwide. 
Tailoring of CDEs and COMs to type of interventional 
frailty studies
When considering the adoption of CDEs and COMs 
to studies of frailty interventions, four types can be 
conceptualized.
1. Type 1. Studies of interventions which aim to modify the 
trajectory of frailty, i.e. an intervention is applied to those 
who are fit or identified as being at risk for, or living with 
frailty and then it is determined whether the intervention is 
able to modify the trajectory of frailty.
2. Type 2. Studies that do not aim to impact frailty severity 
but aim to modify the impact of an intervention on a 
frail population e.g. an intervention is applied to persons 
identified as being frail and the trial aims to determine if a 
related outcome (e.g. health-related quality of life, activities 
of daily living, falls) can be improved.  
3. Type 3. Studies of disease-specific interventions conducted 
where frailty could be an important modifier of the burden or 
outcome of the intervention, i.e. an intervention is applied to 
a population of well-characterised frail and non-frail persons, 
with an a-priori planned analysis of the impact of frailty 
status on the effects of the intervention.
4. Type 4. Studies of health system-level interventions to 
re-organize care or practices to improve outcomes in those 
who are frail, i.e. an intervention is applied to a health 
system and resultant frailty outcomes determined. The 
intervention is not the clinical intervention per se but rather 
the way, by whom, where, or how it is delivered (37). 
Although CDEs should be similar between the four types of 
studies, there was agreement that there would not be primary 
outcome measures that would apply to all. Nevertheless, 
standardization of how outcomes were measured and then 
uniformly applying them across all applicable study types 
will be important. There are likely some secondary outcomes 
that would be applicable to all trials such as the severity of 
frailty and quality of life. For the CDEs, measurement of 
frailty and population descriptors such as co-morbidities, 
medication utilization, caregiver burden and physical and 
cognitive function would be common to all types of frailty 
trials. Although these are important as population descriptors, 
many of them when measured post intervention could also serve 
as outcomes.
Core outcome measures
COMs adopted in frailty trials need to have been evaluated 
for their validity, reliability, utility and responsiveness (38, 39). 
Of particular importance was responsiveness to the intervention 
or the ability of an outcome to change with the intervention 
being studied. 
There was agreement that death should be a secondary 
outcome in frailty trials. Although it is easier to measure 
than other adverse health outcomes, what matters to many 
older adults is not necessarily living longer, but living better 
with functional abilities that enable them to maintain a high 
quality of life (40). The use of death as an outcome stems 
from a disease-based treatment approach and a transformative 
approach relevant to the care of older adults living with frailty 
would be to use a holistic approach based on function. Timing 
of mortality occurrence is important since it may be modifiable 
with an appropriate intervention; however, this should be 
accompanied by measurements of other health characteristics 
such as quality of life since increased longevity may be 
associated with a low quality of life (41).
Physical performance measures that are responsive to change 
(e.g. the Short Physical Performance Battery (SPPB)), and 
are correlated with quality of life would be an option (42, 43). 
Some disadvantages are the clinical burden of performance-
based tests, possible ceiling effects in healthy older adults, and 
floor effects among the severely frail and its responsiveness has 
been called into question (44, 45). 
Accompanying clinical outcomes with robust cost-
effectiveness analyses, including health related quality of life 
allowing derivation of health utility estimates, is especially 
important to influence policy change. 
Common data elements
CDEs should be collected across all frailty clinical studies. 
These would form the minimum data set upon which all 
other data could be collected depending on the type of study, 
intervention, setting, intent of the study and needs of the 
investigator (Figure 1) (46, 47). The elements of the core data 
set would be based upon the domains common to different 
frailty constructs and possibly intrinsic capacity and would be 
as minimal as possible to give investigators and stakeholders 
maximum flexibility.  
Figure 1
Frailty common data elements flower
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There was consensus that chronological age-based or age-
defined inclusion criteria for studies should be avoided since 
aging is very heterogeneous and frailty can start earlier in the 
life course. Conversely, although frailty increases with age, the 
two are not synonymous with only approximately half of older 
adults over the age of 85 living with frailty (48). Instead of age, 
measurement of frailty needs to be understood as an important 
quantifier of risk of potential adverse outcomes. However, 
age may be an important determinant of people’s values and 
preferences, and this should be considered when interpreting 
results.
There was strong agreement that the degree or severity of 
frailty needs to be reported in all studies whose intent is to 
study the impact of an intervention. If conducting a study on 
older patients, there was consensus that the differential impact 
on the sub-population that is frail be reported since the severity 
of frailty may determine responsiveness to the intervention. 
When reporting on frailty, multicomponent frailty measures 
would be considered best to capture all the aspects/dimensions 
of frailty.
There was agreement that important domains of CDEs are 
functional assessment and quality of life. Function is important 
because it is an expression of multiple intrinsic and extrinsic 
dimensions which are often considered when assessing frailty. 
There was also agreement that it is important to shift from 
a disease-based approach to one rooted in function. Frailty 
reflects the predisposition to adverse health outcomes that is 
usually manifested by functional impairment/poor function 
under stress. There was also agreement that quality of life be 
measured in all frailty studies.
In addition to CDEs, studies need to be explicit about 
eligibility criteria and ensure that these are as wide as possible 
since they are directly related to the generalizability and 
effectiveness of trials in the real world. Overall, it is essential 
that CDEs are able to characterize the population and level of 
frailty and ensure that there is the ability to objectively identify 
the population in whom it is to be used. 
Harmonization between frailty constructs and intrinsic 
capacity
There was agreement that harmonizing the frailty constructs 
and the concept of intrinsic capacity using a domains 
perspective would be feasible as the underlying domains 
are similar (Figure 2). This initiative may promote further 
consensus building on a working definition that most parties 
can adopt. There was agreement that it would be best to be 
as inclusive as possible and choosing one model would risk 
excluding a large group of researchers and health systems. 
In addition, if the right data elements are collected, a study 
could be interpreted from a phenotype, a cumulative deficit 
or multidimensional perspective as in intrinsic capacity. In 
addition, there was agreement that a domain be included to 
determine or measure extrinsic characteristics such as social 
vulnerability. If CDEs could be developed with these principles 
in mind, it would be an ideal way to move trials forward along 
with our understanding of frailty and intrinsic capacity. 
Figure 2
Intrinsic capacity, frailty phenotype and frailty index
Frailty can be considered a reflection of diminished intrinsic 
capacity along the life course. When a high level of functional 
reserve is present, frailty does not manifest and there exists a 
high level of intrinsic capacity. When there is little functional 
reserve, as with disability or high levels of frailty, intrinsic 
capacity is low. The concepts of intrinsic capacity and frailty 
are not mutually exclusive and in fact are complementary with 
many of the domains used to measure intrinsic capacity also 
used to measure frailty, based on the frailty index approach 
(49). Frailty in the developed world is associated with advanced 
age and intrinsic capacity attempts to capture the decline of 
health trajectories earlier in the life course by using a healthy 
ageing perspective. However, operationalizing intrinsic 
capacity in a clinical setting has proven to be challenging and 
a collaborative, multidisciplinary and integrated approach is 
needed. This can benefit from the available evidence on frailty 
where commonalities with intrinsic capacity can be used.   
We propose to develop CDEs that allow for the measurement 
of frailty and are compatible with the intrinsic capacity 
framework. To combine the chosen measurements for 
gradation of frailty severity and assessment of longitudinal 
change, we propose a count-based frailty index. At least 30 
metrics would be captured, which is the minimum required 
for stability of frailty severity, with a representative sampling 
of the intrinsic capacity domains (i.e. locomotion, vitality, 
sensory, psychological, cognition) as long as criteria for deficit 
selection was maintained (50). Using the intrinsic capacity 
domains to develop CDEs will allow for the ability to develop 
an optimized list of deficit categories and importantly, would 
include function and cognition which will likely be important 
to stakeholders. In addition, the careful selection of deficit 
categories would allow for multi-dimensional assessment of 
frailty. These would in turn form the minimum dataset to 
characterize the populations enrolled in studies. Although the 
inclusion of 30 items in the frailty index may raise concerns 
about data collection burden, many studies already collect this 
amount of data.
The five items of the Fried Phenotype would be similarly 
captured with CDEs (29). Moreover there is preliminary 
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work to suggest that questions about weakness correlate well 
with handgrip strength, and thus may obviate the need for 
such measurements (10). Once the elements in the frailty 
index are selected, validation of the index would be important 
including the ability to simultaneously measure frailty 
through a deficit model, phenotypic model and ability to 
determine intrinsic capacity. Social parameters are important 
background information, but these are not usually captured. 
How this is handled in the future will need to be decided 
but its incorporation in CDEs is likely important and its 
characterization could be explored in large datasets (51).
Patient/Caregiver engagement
Although the challenges of patient’s engagement are 
recognized, patients and caregivers need to be consulted as the 
process of developing CDEs and COMs proceeds. Using patient 
or caregiver networks may aid in increasing patient/caregiver 
participation. Examples of organizations that maybe helpful in 
this process that were mentioned are: Help Age International 
(http://www.helpage.org/), an organization which reaches many 
countries and has a particularly good representation amongst 
developing nations, the Strategy on Patient-Oriented Research 
(SPOR) units in Canada (http://www.cihr-irsc.gc.ca), the Picker 
Institute Europe at Oxford (http://www.picker.org) and the 
Patient-Centered Outcomes Research Institute (PCORI) (www.
PCORI.org/engagement) in the United States. In addition there 
is an increasing need for patient involvement in frailty research 
and this initiative would be an important springboard for this 
(52, 53). 
Aspects of CDEs or COMs requiring further input from the 
broader community
Scope and Spread of initiative
When and how do we spread the CDEs and COMs initiative? 
Starting with interventional studies may be most feasible but 
observational studies are of great value to study populations 
with frailty and thus their inclusion should be a high priority. 
If possible and contingent on broader consultation, making 
this initiative applicable to all frailty research would be highly 
desirable. Harmonization with administrative data collection 
should be considered in the future recognizing that this type 
of data is usually different than what is reported in research 
studies.  However, research ready administrative data will 
become more available to investigators in the near future 
making harmonization increasingly important and feasible. Two 
examples are as follows. The IMPACT statute in the United 
States will require standardized assessment (e.g. ADLs, IADLs, 
cognitive function) by the end of 2019 in every person who gets 
Medicare-funded after-hospital care (https://www.cms.gov/
Medicare).  In Canada, standardized frailty assessments will be 
required on all inpatient wards in the near future (https://www.
cihi.ca). 
Final selection of domains and Instruments within domains
The final selection of CDE and COM domains and the 
selection of tools and instruments within the domains will 
require broad input from the international community and was 
beyond the scope of this initial meeting. This will be done 
through a Delphi process that would go out to as many nations 
as possible with the possibility that respondents could add 
additional item(s). In this manner geographical differences 
would be captured. The extent of input will directly influence 
the degree to which this initiative is broadly adopted. 
Collaboration with longitudinal studies on aging across the 
world will be important since they are using, have developed, or 
can help validate instruments within domains. These include the 
Canadian Longitudinal Study on Aging (www.clsa-elcv.ca/), 
the Health and Retirement Study (hrsparticipants.isr.umich.
edu/), Survey of Health, Ageing and Retirement in Europe 
(SHARE) (www.share-project.org/ ), The Irish Longitudinal 
Study on Aging (TILDA) (tilda.tcd.ie/), Community Ageing 
Research 75+ (CARE75+) (http://clahrc-yh.nihr.ac.uk/our-
themes/primary-care-based-management-of-frailty-in-older-
people/projects/the-yorkshire-humber-community-ageing-
research-care-study), and the English Longitudinal Study of 
Ageing (www.elsa-project.ac.uk/). These organizations also 
have significant engagement processes and infrastructure that 
may help with our patient engagement needs. Also, the World 
Health Organization has conducted international work on the 
five domains established in the intrinsic capacity initiative and 
would be a good resource for this initiative going forward, 
especially in facilitating consensus building.
 
How we do ensure that patient/caregiver voices are heard
While patients and their family/friend caregivers will be 
in the minority in committees due to practical limitations, we 
must ensure that their voices are heard and reflected in the final 
consensus. For example, in the OMERACT initiative, fatigue 
was identified by patients as an important priority but it did not 
make the final list of “core outcomes” due to criteria requiring 
a majority vote for adoption (54). How a patient’s priorities are 
weighted such that they have a higher chance of inclusion in the 
final measures will require careful consideration and consensus. 
Paid and unpaid caregiver metrics should be included and be 
part of the data sets. These metrics will need to be defined and 
agreed upon. 
Consensus building 
Since it will be important to develop consensus across a wide 
variety of stakeholder groups including clinicians, patients/
caregivers, and decision/policy makers, methods for arriving at 
group consensus will need to be articulated and agreed upon, 
a priori. These stakeholders need to be from a wide variety 
of health systems, regions and countries. There are different 
conceptualizations of frailty and reaching consensus and 
agreement between the various proponents will be important to 
ensure widespread adoption. 
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When and how should this initiative be harmonized with 
non-research initiatives?
Although there was broad consensus that this should 
start as an initiative focused on research, how and when it 
is harmonized with non-research initiatives such as ICHOM 
and administrative databases will require further input and 
discussion. However, if CDEs and COMs are adopted widely 
for frailty studies, that could influence what is collected 
routinely. Importantly, harmonizing with routinely collected 
data, including data definitions, will be important to avoid 
redundancy.
Measurement of the environment in which an intervention 
occurs
Measurement and description of the environment is 
important since context often has important impact on 
outcomes. The provider-patient relationships, behaviours, 
and treatments can all influence the outcome. For example, 
to interpret a study reporting on frailty outcomes, it would 
be important to know about the availability of social and 
community supports. The development of environmental CDEs 
will require further input from the community. 
Consultation with regulatory authorities
Any measures developed could be useful for registration 
trials and thus early consultation with regulatory bodies should 
be part of the process going forward.  The EMA recently 
released a discussion paper describing how to characterize 
baseline frailty status of older patients enrolled in clinical 
trials, other than by age (55). The aim of this statement is 
to ensure that clinical trial populations are representative 
of the medication users as the benefit-risk balance in older 
patients may depend on their frailty status. However, the 
EMA recommended the SPPB and if not possible gait speed, 
which although are correlated with frailty, are one dimensional 
(i.e. physical function) measures. To the present, regulatory 
agencies such as the EMA and FDA have preferred to deal 
with one dimensional constructs rather than heterogeneous 
or multidimensional conditions such as frailty. Increasing 
adoption of frailty CDEs and COMs may encourage regulatory 
agencies to adopt such measures in regulatory trials leading to 
better evaluation of efficacy and safety profiles of medications/
devices likely to be used in patients living with frailty. Along 
with this, there should be an increased emphasis on reporting 
the differential impact of interventions in trials stratified on 
the basis of frailty status and severity along with increased 
inclusion of patients living with frailty in registry trials. 
Harmonization with interRAI
Once the domains of frailty CDEs and COMs are agreed 
upon, if possible, it would be advantageous to harmonize 
domain instruments with ones commonly collected already. 
There are numerous countries where interRAI assessment 
instruments are used and this may represent an opportunity; 
interRAI instruments with known performance characteristics 
could be used to conduct measurements within domains 
(56). Furthermore, when data are available on a population 
basis there is value in being able to compare study data. It is 
estimated that this could be feasible in at least 10 countries 
at the present (www.interrai.org). Further consultation with 
interRAI and stakeholders of this initiative will be required to 
determine if this is possible or desirable once the CDEs and 
COMs domains are finalized.
Policy considerations
It is important to also consider policy perspectives around 
this issue. Frailty challenges the engagement of policy-makers 
because of the large number of instruments/measures and 
lack of consistency across studies (57). Governmental policy-
makers and decision-makers will be key groups to engage. The 
adoption of a common set of measures will result in better data 
and an improved understanding of frailty and its impact. Better 
insights will improve policy formulation, decision making, and 
how health and social organizations work with frail older adults 
and their caregivers, thus achieving greater results than simply 
standardizing data collection for research. Opening a dialogue 
with policy makers in variety of jurisdictions around the world 
will be important as this initiative moves forward.
Better characterization of frail populations
Although a holistic approach to frailty is always going to be 
required, the group felt that there is a need to better characterize 
frail populations informed by genetics or biomarkers. An 
analogy is the evolution in our understanding of diabetes from 
a type 1/2 classification to a genetically influenced sub-type 
classification (58).  In the future, we may be able to better 
characterize frailty status based on an individual’s biomarker 
profile (www.frailomic.org). As the frailty CDEs and COMs 
develop over time, frailty biomarkers could be used to 
additionally characterize frail populations (59, 60). Further 
research and consultation with the basic science community is 
required and has been started (61). 
Need to measure burden of the intervention
The burden of an intervention, which likely is different 
for non-frail older adults versus older adults with frailty, may 
be an important moderator of clinical effectiveness and cost-
effectiveness. Usually non-adherence to the intervention is 
reported but better measures of burden need to be developed 
and reported.
Next Step
An executive committee for this initiative has been convened 
with international representation. The main objective of this 
committee is to identify key partners around the world and 
develop a process for consensus building. The committee will 
guide the design of the international Delphi process, including 
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the elements of the survey and its broad distribution.
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